Longboard Pharmaceuticals has displayed a staggering YTD performance of +875.79%, significantly outpacing the S&P 500’s +22.85%. This impressive rise highlights not just the company’s operational ...
H. Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing ...
Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2.6 billion equity value. Longboard Pharmaceuticals shares jumped 46.8% to $57.13 in the pre-market ...